Rehovot, Israel (ots/PRNewswire) - Israel becomes the first country
in the world to grant medical device approval for a medical cannabis
vaporizer
Kanabo Research, a Tel-Aviv-based medical cannabis R&D company, is
pleased to announce that the Israeli Ministry of Health has granted
initial approval as a medical device to its VapePod vaporizer
product. This action makes Israel the first county in the world to
grant medical device approval to a vaporizer for the use of medical
cannabis extracts and formulations.
In addition, Kanabo has initiated initial pre-clinical trials of the
company's targeted formulations for sleep disorders, designed for use
with the approved VapePod medical cannabis vaporizer, and is
achieving impressive results in early findings.
The combination of the approved vaporizer and the targeted
formulations will enable medical cannabis patients to receive more
effective, consistent, and accurate dosing and delivery methods than
currently accepted medical cannabis treatment methods. Kanabo has two
patents in the process of registration regarding the targeted
formulations of medical cannabis extracts for sleep disorders, as
well as the initial approval of the VapePod vaporizer by the Medical
Cannabis Unit of the Israeli Ministry of Health.
Most medical cannabis patients today consume their cannabis by
smoking - despite all of the known risks. The VapePod medical
vaporizer enables patients to inhale their medical cannabis without
the risks of smoking. Studies have shown that inhaling cannabis is
significantly more effective than other delivery methods, and the
VapePod vaporizer allows patients to still utilize the benefits of
inhalation. The next version of the device - VapePod MD - will also
monitor patient usage and gather usage data for caregivers, doctors,
and research applications.
"This approval is a significant announcement for the medical cannabis
patients in Israel who will be able to use the medical vaporizer for
the first time," said Avihu Tamir, co-founder and CEO of Kanabo
Research. "We expect that due to the transition of most of the
cannabis consumers to the use of vaporizers, our company is projected
to reach 10 million dollars in sales within three years in the
Israeli market, while the Israeli cannabis market is expected to
reach 100 million dollars in sales within three years. The Israeli
market is a platform to deliver our technology to global markets in
North America and Europe."
ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN
